市場調査レポート

2016年までの治療的蛋白質の市場:薬剤、装置、疾病、市場、及び将来予測

Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts

発行 Greystone Research Associates 商品コード 239578
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
2016年までの治療的蛋白質の市場:薬剤、装置、疾病、市場、及び将来予測 Therapeutic Proteins to 2016: Drugs, Devices, Diseases, Markets and Forecasts
出版日: 2012年05月01日 ページ情報: 英文
概要

近年、市場に到達する蛋白質性医薬品の数は急増しています。これらの薬品の臨床的応用は、適正な吸収と分布に対する望ましい特性が不十分であることにより制限されているため、安全で安定し、効果的な送達システムを備えた薬品を製剤することが最重要となっています。

当レポートでは、承認済みの治療的蛋白質製品とパイプライン候補薬、既存薬品と将来有望な蛋白質性医薬品、蛋白質の送達設計上の問題/包装/流通/技術的要因、蛋白質の製剤決定による治療的蛋白質の商業化/市場潜在力に対する影響、9つの主要治療部門の歴史的データと2016年までの疾病部門別の将来予測、企業プロファイルと各社の市販製品/製品開発活動/事業的戦略などについて詳細に調査・分析し、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリ

第2章 蛋白質治療市場の動態

  • 蛋白質治療市場
  • 臨床試験と薬剤の承認
  • 競合状況
  • 人口統計、管理医療、成長
  • リスクと機会

第3章 治療的蛋白質の商業化:成功要因

  • 蛋白質性医薬品の製剤

第4章 蛋白質性医薬品の流通戦略

第5章 蛋白質性医薬品:薬剤クラスと治療的標的

  • 抗体
  • 酵素
  • 成長因子
  • 造血
  • ホルモン
  • 免疫変調成分
  • その他の蛋白質治療クラス

第6章 蛋白質性医薬品の治療:疾病部門の分析と将来予測

  • 自己免疫疾患
  • 血液学
  • 遺伝性疾患
  • 感染症
  • ホルモン補充
  • 腫瘍学
  • 生殖医療
  • 移植/臓器拒絶反応
  • 新興治療部門

第7章 市場/規制的要因

  • 規制的問題
  • 使用の容易性と患者のコンプライアンス
  • IPとバイオシミラー

第8章 蛋白質性医薬品治療:企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: DTP268B

Abstract

In recent years, the number of protein - based pharmaceuticals reaching the marketplace has increased exponentially. The clinical application of these drugs is limited by a lack of desirable attributes for adequate absorption or distribution. It therefore becomes critical to formulate these drugs into safe, stable and efficacious delivery systems. Because these drugs face formidable enzymatic and penetration barriers when administered orally, peptide and protein drugs continue to be developed almost exclusively for parenteral administration. These combination drug-device products, where the drug and device are clinically tested and approved as a single product entity, are becoming one of the fastest new drug categories. The growth of protein drug products is having a significant effect on the way drugs and devices are developed. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies.

Highlights

  • Analyzes approved therapeutic protein products and pipeline candidates and assesses the market potential for existing and probable future protein drugs
  • Examines protein delivery design issues, packaging, distribution and technology factors
  • Assesses the role of protein formulation decisions on therapeutic protein commercialization and market potential
  • Examines historical protein drug data for nine major therapeutic segments and provides forecasts by disease segment to 2016
  • Profiles therapeutic protein companies, their commercial products, product development activity, and business strategies

Table of Contents

Executive Summary

Protein Therapeutics Market Dynamics

  • The Protein Therapeutics Marketspace
  • Clinical Trials and Drug Approvals
  • The Competitive Landscape
  • Demographics, Managed Care and Growth
  • Risks and Opportunities

Therapeutic Protein Commercialization - Success Factors

  • Formulating Protein Drugs
    • Formulation Strategies
      • Stability
      • Half - Life & Therapeutic Protocols
      • Immunogenicity
    • Protein Formulation Technologies
      • Post - translational Modification
      • Encapsulation Technologies
      • Lyophilization
    • Dosing Frequency and Treatment Compliance
    • Protein Packaging & Delivery
      • Injection
        • Pen Injectors - Dominant in Chronic Disease
        • Prefilled Syringes - Evolving Technology, Expanding Reach
        • Emerging Protein Injection Options
      • Inhalation
        • Dry Powder Inhalers - Stability at a Price
        • Sprays/Aerosols - The Technical Challenges
      • Development-stage Packaging & Delivery Technologies
        • Oral
          • Proprietary Processes and Pipeline Prospects
          • Commercialization Potential & Risk Factors
        • Transdermal
          • Transdermal - Obstacles and Limitations
          • Microneedles - Engineering & Economics

Protein Drug Distribution Strategies

Protein Drugs - Drug Classes and Therapeutic Targets

  • Antibodies
  • Enzymes
  • Growth Factors
  • Hematopoietics
  • Hormones
  • Immune Modulators
  • Other Protein Therapy Classes

Protein Drug Therapeutics - Disease Segment Analysis & Forecasts

  • Autoimmune Diseases
    • Dominance of Antibodies & Cytokines
    • B-Cell Depleting Agents
    • Interferons
    • Interleukin Receptor Agonists
    • TNF Inhibitors
    • T-Cell Blocking Agents
    • Development-stageCandidates
    • Demand Patterns and Forecasts
  • Hematology
    • Anemia
    • Hemoglobinuria
    • Thrombocytopenia
    • Demand Patterns and Forecasts
  • Hereditary Diseases
  • Infectious Diseases
    • Hepatitis
    • RSV
    • Demand Patterns and Forecasts
  • Hormone Replacement
    • Increasing Competition in a Crowded Market
    • Demand Factors and Forecasts
  • Oncology
    • Key Therapeutic Sectors & Therapeutic Target Selection
    • Expanding Indications & Therapeutic Endpoints
    • Leading Oncology Protein Drug Products
    • Pipeline Candidates
    • Demand Data and Forecasts
  • Reproductive Medicine
    • Dominance of Leutinizing Hormones
    • Demand Data and Forecasts
  • Transplantation/Organ Rejection
    • Approve Protein Drugs
    • The Market Opportunity
  • Emerging Therapeutic Segments

Market and Regulatory Factors

  • Regulatory Issues
  • Ease - of - Use and Patient Compliance
  • IP and Biosimilars

Protein Drug Therapeutics - Company Profiles

Back to Top